|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:European_Union
2014
|
|
gptkbp:ATCCode
|
M09AX03
|
|
gptkbp:brand
|
gptkb:Translarna
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:PTC_Therapeutics
|
|
gptkbp:form
|
oral suspension
granules for oral suspension
|
|
gptkbp:genericName
|
ataluren
|
|
gptkbp:indication
|
nonsense mutation Duchenne muscular dystrophy
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:PTC_Therapeutics
|
|
gptkbp:mechanismOfAction
|
promotes ribosomal readthrough of nonsense mutations
|
|
gptkbp:orphanDrugStatus
|
yes
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:regulates
|
gptkb:European_Medicines_Agency
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
headache
|
|
gptkbp:targetAudience
|
patients with nonsense mutation DMD aged 2 years and older
|
|
gptkbp:usedFor
|
gptkb:Duchenne_muscular_dystrophy
|
|
gptkbp:bfsParent
|
gptkb:PTC_Therapeutics
gptkb:Ataluren
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Translarna
|